Last reviewed · How we verify

addition of azathioprine

Védrines, Philippe, M.D. · FDA-approved active Small molecule

addition of azathioprine is a Purine analog immunosuppressant Small molecule drug developed by Védrines, Philippe, M.D.. It is currently FDA-approved for Rheumatoid arthritis, Systemic lupus erythematosus, Inflammatory bowel disease (Crohn's disease and ulcerative colitis).

Azathioprine is a purine analog that inhibits T-cell and B-cell proliferation by interfering with nucleotide synthesis, thereby suppressing immune responses.

Azathioprine is a purine analog that inhibits T-cell and B-cell proliferation by interfering with nucleotide synthesis, thereby suppressing immune responses. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Inflammatory bowel disease (Crohn's disease and ulcerative colitis).

At a glance

Generic nameaddition of azathioprine
SponsorVédrines, Philippe, M.D.
Drug classPurine analog immunosuppressant
TargetInosine monophosphate dehydrogenase (IMPDH), hypoxanthine-guanine phosphoribosyltransferase (HGPRT)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Azathioprine is converted to 6-mercaptopurine, which is further metabolized to active nucleotide analogs that inhibit both de novo and salvage pathways of purine synthesis. This leads to reduced proliferation of lymphocytes and decreased production of immunoglobulins and cytokines, making it effective as an immunosuppressant in autoimmune and inflammatory conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about addition of azathioprine

What is addition of azathioprine?

addition of azathioprine is a Purine analog immunosuppressant drug developed by Védrines, Philippe, M.D., indicated for Rheumatoid arthritis, Systemic lupus erythematosus, Inflammatory bowel disease (Crohn's disease and ulcerative colitis).

How does addition of azathioprine work?

Azathioprine is a purine analog that inhibits T-cell and B-cell proliferation by interfering with nucleotide synthesis, thereby suppressing immune responses.

What is addition of azathioprine used for?

addition of azathioprine is indicated for Rheumatoid arthritis, Systemic lupus erythematosus, Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Autoimmune hepatitis, Organ transplant rejection prevention.

Who makes addition of azathioprine?

addition of azathioprine is developed and marketed by Védrines, Philippe, M.D. (see full Védrines, Philippe, M.D. pipeline at /company/v-drines-philippe-m-d).

What drug class is addition of azathioprine in?

addition of azathioprine belongs to the Purine analog immunosuppressant class. See all Purine analog immunosuppressant drugs at /class/purine-analog-immunosuppressant.

What development phase is addition of azathioprine in?

addition of azathioprine is FDA-approved (marketed).

What are the side effects of addition of azathioprine?

Common side effects of addition of azathioprine include Bone marrow suppression (leukopenia, thrombocytopenia), Nausea and vomiting, Hepatotoxicity, Infections, Pancreatitis, Alopecia.

What does addition of azathioprine target?

addition of azathioprine targets Inosine monophosphate dehydrogenase (IMPDH), hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and is a Purine analog immunosuppressant.

Related